“These five top stocks are all on the BofA Securities US 1 list of top picks. They all are very prominent in their respective silos in the financial and health care sectors, and all are great second-quarter ideas for growth investors with a little bit of risk tolerance looking to rotate capital,” says the author of today’s article of the…
When it comes to creating a useful profile for monster growth stocks, the author of today’s article lays out the following criteria: “gangbusters gains, Buy ratings from the Wall Street analyst corps, and considerable upside for the coming year.” With that, he proceeds to highlight three stocks that meet the profile for monster growth, including one that “puts a different…
“The company highlighted in today’s article “helps its customers to find the exceedingly rare cells/antibodies needed to fight cancer, inflammation etc. Basically, to find the needle in the haystack” – and as it operates in a high-growth and rapidly expanding area of biotech, the author believes that this digital cell biology company is a solid candidate for high-growth/high-risk portfolios. For…
In the biotech realm, the author of today’s article notes that “PDUFA (Prescription Drug User Fee Act) dates – the deadline of the FDA’s review of new drugs – determine whether a treatment is fit for purpose or not and a yay or nay can act as a major catalyst to send shares either soaring or crashing.” As such, he…
What’s the best proxy for the trends that can help you make money? The answer may be the 50-day moving average, which the author of today’s article advises “is in the goldilocks zone of not being too short or too long.” Using the example of a potentially game-changing stock from the green energy sector, he outlines how traders can use…
While more suited for aggressive investors, and with the number of new traders skyrocketing over the past year and making good ideas to trade even harder to find, these could prove exciting additions for traders looking for solid alpha potential,” says the author of today’s article of the five Buy-rated stocks currently trading under $10 that he proceeds to highlight.…
With the daily average coronavirus cases being above 150,000 in the U.S., investors have been going back to the old playbook that worked so well last year. This could explain why the tech sector is still performing so well,” notes the author of today’s article before proceeding to highlight four tech stocks in particular to watch this week. For these…
“While more suited for aggressive investors, and with the number of new traders skyrocketing over the past year and making good ideas to trade even harder to find, these could prove exciting additions for traders looking for solid alpha potential,” says the author of today’s article in regards to five Buy-rated stocks priced under $10 that he proceeds to highlight.…
While biotech stocks have been hot over the last year, today’s article notes that another group of stocks have been trading like biotech companies of late: psychedelic stocks. In fact, a slew of psychedelic stocks have posted triple-digit returns over the last year – and with the impending release of studies examining the use of psychedelics to treat mental health…
The thing that created the conditions that made 2020 so awful for so many – the coronavirus pandemic – also created the conditions for tech to stage an impressive rally. The three promising tech stocks highlighted in today’s article, however, did not participate in that rally. As a result, these underperforming stocks “still trade at levels that leave room for…